Nonhematologic serious adverse events (all grade 4 and 5 toxicities, and grade 3 toxicities occurring in ≥ 2 patients)
| Event . | Grade . | Total . | Patients, %* . | ||
|---|---|---|---|---|---|
| 3 . | 4 . | 5 . | |||
| Sepsis, n | 1 | 1 | 3.3 | ||
| Liver failure, n | 1 | 1 | 3.3 | ||
| Renal failure, n | 1 | 1 | 3.3 | ||
| Peripheral neuropathy, n | 2 | 2 | 6.7 | ||
| Fatigue, n | 2 | 2 | 6.7 | ||
| Hypotension, n | 2 | 2 | 6.7 | ||
| Herpes zoster, n | 2 | 2 | 6.7 | ||
| Dehydration, n | 2 | 2 | 6.7 | ||
| Event . | Grade . | Total . | Patients, %* . | ||
|---|---|---|---|---|---|
| 3 . | 4 . | 5 . | |||
| Sepsis, n | 1 | 1 | 3.3 | ||
| Liver failure, n | 1 | 1 | 3.3 | ||
| Renal failure, n | 1 | 1 | 3.3 | ||
| Peripheral neuropathy, n | 2 | 2 | 6.7 | ||
| Fatigue, n | 2 | 2 | 6.7 | ||
| Hypotension, n | 2 | 2 | 6.7 | ||
| Herpes zoster, n | 2 | 2 | 6.7 | ||
| Dehydration, n | 2 | 2 | 6.7 | ||
Percentage of patients who started treatment (n = 30).